Yes, GC has consistently stated bridge data in Q3. It might be top line results for 72 patients at the time but still good. I say that because they said they might add patients to power the data sets and I don't know how long that takes or if they were already adding when he said 'might'. My guess is they were adding patients to power the ability to detect stages of Alzheimer's. This is the stage independent aspect of the test that is such a massive benefit for the product.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links